certolizumab pegol vs golimumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT00552344 · Phase 3 · completed
This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)
Result source: NCT00552058
golimumab · Simponi
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | certolizumab pegol | golimumab |
|---|---|---|
| Clinical remission (induction) | 31.6% vs 25.4%+6.2 vs placeboNCT005520582 other results
| —Not reported |
| Endoscopic response (induction) | —Not posted · NCT00152425 | —Not reported |
| Clinical remission (maintenance) | 37.5% vs 35%+2.5 vs placeboNCT003564081 other result
| —Not reported |
| Endoscopic response (maintenance) | —Not posted · NCT00152425 | —Not reported |
Clinical remission (induction)
- certolizumab pegol
- 31.6% vs 25.4%+6.2 vs placeboNCT00552058
2 other results
- 26.5% vs 19.1% NCT00552058
- 23.3% vs 15.8% NCT00552058
- golimumab
- —Not reported
Endoscopic response (induction)
- certolizumab pegol
- —Not posted · NCT00152425
- golimumab
- —Not reported
Clinical remission (maintenance)
- certolizumab pegol
- 37.5% vs 35%+2.5 vs placeboNCT00356408
1 other result
- 3% vs 35% NCT00356408
- golimumab
- —Not reported
Endoscopic response (maintenance)
- certolizumab pegol
- —Not posted · NCT00152425
- golimumab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
golimumab: registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. certolizumab pegol: 4 of 4 rows · golimumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | certolizumab pegol |
|---|---|
| Dropout rate | 78.4%a NCT00552344 · Phase 3 · monotherapy show 24 more results80.3% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 69.5%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 92.3% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 7.2% NCT00552058 · Phase 3 · monotherapy 40.4%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 46.2%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 53.3%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 25%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 3.1%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00552344 · Phase 3 · monotherapy show 24 more results35.8% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 18.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 51% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 3.6% NCT00552058 · Phase 3 · monotherapy 14.6%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence —400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence —400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 12.5%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence —400 mg NCT00291668 · Phase 2 · registry result, not featured evidence —200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 37.1%a NCT00552344 · Phase 3 · monotherapy show 24 more results40.3% NCT00160524 · Phase 3 · monotherapy 13.4%400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy 13.4%400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 31.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 44.5% NCT00160706 · Phase 3 · monotherapy 14.6%400 mg NCT00356408 · Phase 3 · monotherapy 0%CDP870/Completer NCT00356408 · Phase 3 · monotherapy 12.1%CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 5.4% NCT00552058 · Phase 3 · monotherapy 38.2%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 0%Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 40%High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 0%Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 50%Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 23.1%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 33.3%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 31.3%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 9.4%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a crohn's disease 31.6% abdominal pain 18.7% upper respiratory tract infection 15.7% NCT00552344 · Phase 3 · monotherapy show 21 more results400 mg every 2 weeks nasopharyngitis 17.2% pyrexia 11.8% arthralgia 10.8% NCT00308581 · Phase 3 · monotherapy 400 mg every 4 weeks headache 16.6% nasopharyngitis 12.3% nausea 11.2% NCT00308581 · Phase 3 · monotherapy 400 mg nasopharyngitis 27.5% headache 20.5% pyrexia 20.5% NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 400 mg crohn's disease 21.4% (placebo 7.1%) arthralgia 18.4% (placebo 0%) upper respiratory tract infection 13.6% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy arthralgia 25% (placebo 0%) myalgia 18.8% (placebo 0%) sinusitis 18.8% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy crohn's disease 33.3% (placebo 7.1%) arthralgia 21.2% (placebo 0%) nausea 18.2% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy headache 5.4% (placebo 4.7%) abdominal pain 4.5% (placebo 3.7%) arthralgia 4% (placebo 2.8%) NCT00552058 · Phase 3 · monotherapy 400 mg headache 33.7% arthralgia 30.3% nasopharyngitis 23.6% NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 High-dose (Weight Adjusted) abdominal pain upper 40% nasopharyngitis 20% nausea 20% NCT01190410 · Phase 2 · registry result, not featured evidence Low-dose (Weight Adjusted) asthma exercise induced 25% cough 25% dizziness 25% NCT01190410 · Phase 2 · registry result, not featured evidence Re-Induction abdominal injury 50% anal fissure 50% c-reactive protein increased 50% NCT01190410 · Phase 2 · registry result, not featured evidence 400 mg / 200 mg pyrexia 46.2% (placebo 11.1%) nasopharyngitis 38.5% (placebo 55.6%) contusion 15.4% (placebo 0%) NCT00329420 · Phase 2 · registry result, not featured evidence 400 mg / 400 mg nasopharyngitis 40% (placebo 55.6%) pyrexia 20% (placebo 11.1%) nausea 13.3% (placebo 5.6%) NCT00329420 · Phase 2 · registry result, not featured evidence nasopharyngitis 20% (placebo 22.2%) nausea 13.3% (placebo 22.2%) urinary tract infection 13.3% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence nasopharyngitis 62.5% (placebo 22.2%) dna antibody positive 12.5% (placebo 22.2%) headache 12.5% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence 400 mg nasopharyngitis 21.9% (placebo 31.3%) nausea 6.3% (placebo 3.1%) pharynx discomfort 6.3% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 23.3% (placebo 31.3%) nausea 6.7% (placebo 3.1%) pharyngolaryngeal pain 6.7% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 21 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
certolizumab pegol
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 19 more results
show 19 more results
show 1 more result
show 17 more results
show 17 more results
show 2 more results
+ 28 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT03357471 · Phase 3 · completed
Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.
No aligned efficacy figure on record for this race.
golimumab · Simponi
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Reported efficacy
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% (met)
Result source: NCT02181673
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | certolizumab pegol | golimumab |
|---|---|---|
| ACR20 | 51.9% vs 24.3%+27.6 vs placeboNCT010877883 other results
| 45.2% vs 8.8%+36.4 vs placeboNCT002650966 other results
|
| ACR50 | —Not reported | 53.5% vs 6.3%+47.2 vs placeboNCT021816735 other results
|
| PASI 75 | 60.5% vs 15.1%+45.4 vs placeboNCT010877881 other result
| 58.3% vs 2.5%+55.8 vs placeboNCT002650966 other results
|
| Minimal disease activity | —Not reported | 39.5% vs 48.8%vs MethotrexateNCT041084683 other results
|
| HAQ-DI, change | -0.5 vs -0.2−0.3 vs placeboNCT010877881 other result
| 0.4 vs 0+0.4 vs placeboNCT002650962 other results
|
ACR20
- certolizumab pegol
- 51.9% vs 24.3%+27.6 vs placeboNCT01087788
3 other results
- 58% vs 24.3% NCT01087788
- 56.3% vs 23.5% NCT01087788
- 63.8% vs 23.5% NCT01087788
- golimumab
- 45.2% vs 8.8%+36.4 vs placeboNCT00265096
6 other results
- 50.7% vs 8.8% NCT00265096
- 75.1% vs 21.8% NCT02181673
- 65.1% vs 65.9% NCT04108468
- 65.1% vs 56.1% NCT04108468
- 62.8% vs 58.5% NCT04108468
- 53.5% vs 68.3% NCT04108468
ACR50
- certolizumab pegol
- —Not reported
- golimumab
- 53.5% vs 6.3%+47.2 vs placeboNCT02181673
5 other results
- 43.6% vs 6.3% NCT02181673
- 37.2% vs 36.6% NCT04108468
- 48.8% vs 39% NCT04108468
- 48.8% vs 36.6% NCT04108468
- 46.5% vs 29.3% NCT04108468
PASI 75
- certolizumab pegol
- 60.5% vs 15.1%+45.4 vs placeboNCT01087788
1 other result
- 62.2% vs 15.1% NCT01087788
- golimumab
- 58.3% vs 2.5%+55.8 vs placeboNCT00265096
6 other results
- 40.4% vs 2.5% NCT00265096
- 59.2% vs 13.6% NCT02181673
- 84.6% vs 37.5% NCT04108468
- 53.8% vs 0% NCT04108468
- 69.2% vs 25% NCT04108468
- 46.2% vs 25% NCT04108468
Minimal disease activity
- certolizumab pegol
- —Not reported
- golimumab
- 39.5% vs 48.8%vs MethotrexateNCT04108468
3 other results
- 58.1% vs 53.7% NCT04108468
- 55.8% vs 58.5% NCT04108468
- 46.5% vs 43.9% NCT04108468
HAQ-DI, change
- certolizumab pegol
- -0.5 vs -0.2−0.3 vs placeboNCT01087788
1 other result
- -0.5 vs -0.2 NCT01087788
- golimumab
- 0.4 vs 0+0.4 vs placeboNCT00265096
2 other results
- 0.3 vs 0 NCT00265096
- -0.6 vs -0.1 NCT02181673
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. certolizumab pegol: 4 of 4 rows · golimumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | certolizumab pegol | golimumab Rows use multiple source trials |
|---|---|---|
| Dropout rate | —400 mg Q4Wa NCT01087788 · Phase 3 show 6 more results—200 mg Q2W NCT01087788 · Phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence | 6%b NCT03733925 · Phase 4 · registry result, not featured evidence show 7 more results9.3% NCT04108468 · Phase 3 · registry result, not featured evidence · combination 4.8% NCT02065713 · Phase 3 · registry result, not featured evidence · combination 4.6%2 mg/kg NCT02181673 · Phase 3 · registry result, not featured evidence —100 mg NCT00265096 · Phase 3 · registry result, not featured evidence —50 and 100 mg NCT00265096 · Phase 3 · registry result, not featured evidence —50 mg NCT00265096 · Phase 3 · registry result, not featured evidence 18.6%100 mg q4w + 50 mg q4w NCT05071664 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —400 mg Q4Wa NCT01087788 · Phase 3 show 6 more results—200 mg Q2W NCT01087788 · Phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence | 2%b NCT03733925 · Phase 4 · registry result, not featured evidence show 7 more results— NCT04108468 · Phase 3 · registry result, not featured evidence · combination 4.8% NCT02065713 · Phase 3 · registry result, not featured evidence · combination 1.2%2 mg/kg NCT02181673 · Phase 3 · registry result, not featured evidence —100 mg NCT00265096 · Phase 3 · registry result, not featured evidence —50 and 100 mg NCT00265096 · Phase 3 · registry result, not featured evidence —50 mg NCT00265096 · Phase 3 · registry result, not featured evidence —100 mg q4w + 50 mg q4w NCT05071664 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 26.2%400 mg Q4Wa NCT01087788 · Phase 3 show 6 more results24.7%200 mg Q2W NCT01087788 · Phase 3 0%Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence | 4%b NCT03733925 · Phase 4 · registry result, not featured evidence show 7 more results0% NCT04108468 · Phase 3 · registry result, not featured evidence · combination 0% NCT02065713 · Phase 3 · registry result, not featured evidence · combination 7.9%2 mg/kg NCT02181673 · Phase 3 · registry result, not featured evidence 22.9%100 mg NCT00265096 · Phase 3 · registry result, not featured evidence 19.9%50 and 100 mg NCT00265096 · Phase 3 · registry result, not featured evidence 20.9%50 mg NCT00265096 · Phase 3 · registry result, not featured evidence 6.8%100 mg q4w + 50 mg q4w NCT05071664 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 400 mg Q4Wa upper respiratory tract infection 25.1% nasopharyngitis 21.5% pharyngitis 13.8% NCT01087788 · Phase 3 show 3 more results200 mg Q2W nasopharyngitis 22.7% upper respiratory tract infection 22.2% hypertension 15.2% NCT01087788 · Phase 3 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence | show 7 more resultsalanine aminotransferase increased 48.8% upper respiratory infection 41.9% nausea 37.2% NCT04108468 · Phase 3 · registry result, not featured evidence · combination arthralgia 14.3% (placebo 4.3%) folliculitis 14.3% (placebo 0%) transaminases increased 14.3% (placebo 17.4%) NCT02065713 · Phase 3 · registry result, not featured evidence · combination 2 mg/kg alanine aminotransferase increased 10.4% (placebo 2.1%) aspartate aminotransferase increased 7.9% (placebo 2.1%) nasopharyngitis 5.8% (placebo 5.4%) NCT02181673 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 31.2% nasopharyngitis 25.7% back pain 16.5% NCT00265096 · Phase 3 · registry result, not featured evidence 50 and 100 mg upper respiratory tract infection 28.1% nasopharyngitis 21.2% hypertension 16.4% NCT00265096 · Phase 3 · registry result, not featured evidence 50 mg upper respiratory tract infection 31.7% nasopharyngitis 16.5% headache 15.1% NCT00265096 · Phase 3 · registry result, not featured evidence 100 mg q4w + 50 mg q4w diarrhoea 11.9% headache 11.9% covid-19 8.5% NCT05071664 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 5 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
certolizumab pegol
show 1 more result
show 1 more result
golimumab
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 1 more result
+ 19 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT03357471 · Phase 3 · completed
Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Reported efficacy
Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Certolizumab Pegol Q2W Injection by e-Device (SS) 100 percentage of subjects (95% CI 91.3 to 100) | Certolizumab Pegol Q4W Injection by e-Device (SS) 96.88 percentage of subjects (95% CI 86 to 99.8)
Result source: NCT03357471
golimumab · Simponi
Marketed by Johnson & Johnson
NCT00264537 · Phase 3 · completed
This trial was well designed -- randomized, fully blinded, and placebo-controlled with over 600 patients -- but its two main outcomes told different stories: the joint-damage (structural) outcome clearly favored golimumab plus methotrexate, while the joint-response (ACR50) outcome for the combined golimumab groups narrowly missed statistical significance against placebo, with only one of the individual dose comparisons reaching significance on its own. A well-designed trial with a split result on its co-primary outcomes does not qualify as strong evidence of benefit.
Reported efficacy
ACR20 response at week 14; change from baseline in HAQ score at week 24: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. (met)
Result source: NCT00264550
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | certolizumab pegol | golimumab |
|---|---|---|
| ACR20 | 54.8% vs 23.9%+30.9 vs placeboNCT0215185121 other results
| 44.4% vs 33.1%+11.3 vs placeboNCT0026455025 other results
|
| ACR50 | 36.5% vs 7.1%+29.4 vs placeboNCT0215185111 other results
| 32.7% vs 29.4%+3.3 vs placeboNCT0026453719 other results
|
| ACR70 | 51.3% vs 39.9%+11.4 vs placeboNCT015197919 other results
| 16.1% vs 25.9%vs GolimumabNCT01715896 |
| DAS28-CRP remission | 16% vs 5.7%+10.3 vs placeboNCT00717236 | —Trial running · NCT03414502 |
| HAQ-DI, change | -0.5 vs -0.2−0.3 vs placeboNCT021518518 other results
| 0.1 vs 0.1±0 vs placeboNCT002645508 other results
|
| Modified Sharp score, change | 0.4 vs 1.6−1.2 vs placeboNCT014512036 other results
| 1.3 vs 1.4−0.1 vs placeboNCT0026453711 other results
|
ACR20
- certolizumab pegol
- 54.8% vs 23.9%+30.9 vs placeboNCT02151851
21 other results
- 51.1% vs 25.9% NCT00717236
- 77.6% vs 28.6% NCT00791999
- 67.2% vs 14.9% NCT00791921
- 76.8% vs 28.6% NCT00791999
- 62.5% vs 28.6% NCT00791999
- 66.7% vs 27.5% NCT00993317
- 69% vs 61.5% NCT01519791
- 71.8% vs 24.7% NCT00791999
- 36.5% vs 15.3% NCT00674362
- 63.8% vs 11.4% NCT00791921
- 73.2% vs 24.7% NCT00791999
- 61.1% vs 24.7% NCT00791999
- 64.2% vs 37.5% NCT00993317
- 86.5% vs 74.7% NCT01521923
- 73.8% vs 74.7% NCT01521923
- 65.2% vs 44.9% NCT00580840
- 67.1% vs 44.9% NCT00580840
- 61.5% vs 0% NCT01147341
- 69.2% vs 71.4% NCT01500278
- 54.5% vs 62.5% NCT01147341
- 64.5% vs 60.8% NCT01500278
- golimumab
- 44.4% vs 33.1%+11.3 vs placeboNCT00264550
25 other results
- 36.5% vs 18% NCT00299546
- 40.9% vs 15.9% NCT01248780
- 34.7% vs 18% NCT00299546
- 58.5% vs 24.9% NCT00973479
- 56.2% vs 33.1% NCT00264550
- 55.1% vs 33.1% NCT00264550
- 51.6% vs 49.4% NCT00264537
- 35.3% vs 27.8% NCT00264550
- 42.6% vs 16% NCT00299546
- 42.4% vs 15.9% NCT01248780
- 31.3% vs 16% NCT00299546
- 48.1% vs 27.9% NCT00361335
- 39.8% vs 27.9% NCT00361335
- 61.6% vs 49.4% NCT00264537
- 61.6% vs 49.4% NCT00264537
- 61.6% vs 49.4% NCT00264537
- 59.6% vs 27.8% NCT00264550
- 59.6% vs 27.8% NCT00264550
- 51.6% vs 27.9% NCT00361335
- 55% vs 27.9% NCT00361335
- 55.9% vs 37.1% NCT00207714
- 79.4% vs 37.1% NCT00207714
- 60% vs 37.1% NCT00207714
- 50% vs 37.1% NCT00207714
- 62% vs 65.6% NCT01715896
ACR50
- certolizumab pegol
- 36.5% vs 7.1%+29.4 vs placeboNCT02151851
11 other results
- 26.6% vs 9.9% NCT00717236
- 61.8% vs 52.6% NCT01519791
- 20.8% vs 7.1% NCT00674362
- 43.2% vs 20% NCT00993317
- 25.9% vs 12.5% NCT00993317
- 80.2% vs 68.4% NCT01521923
- 71.4% vs 68.4% NCT01521923
- 52.2% vs 30.4% NCT00580840
- 50% vs 30.4% NCT00580840
- 27.3% vs 37.5% NCT01147341
- 19.2% vs 0% NCT01147341
- golimumab
- 32.7% vs 29.4%+3.3 vs placeboNCT00264537
19 other results
- 19.4% vs 13.2% NCT00361335
- 12.5% vs 13.2% NCT00361335
- 36.5% vs 29.4% NCT00264537
- 40.3% vs 29.4% NCT00264537
- 21.1% vs 13.2% NCT00361335
- 21.7% vs 13.2% NCT00361335
- 38.4% vs 29.4% NCT00264537
- 18.2% vs 6.7% NCT00299546
- 15% vs 6.7% NCT00299546
- 34.9% vs 13.2% NCT00973479
- 28.9% vs 35.8% NCT00264537
- 11.6% vs 9.3% NCT00361335
- 8.6% vs 9.3% NCT00361335
- 44.6% vs 35.8% NCT00264537
- 44.2% vs 35.8% NCT00264537
- 25% vs 9.3% NCT00361335
- 18.6% vs 9.3% NCT00361335
- 44.4% vs 35.8% NCT00264537
- 34.8% vs 43.4% NCT01715896
ACR70
- certolizumab pegol
- 51.3% vs 39.9%+11.4 vs placeboNCT01519791
9 other results
- 12.9% vs 2.8% NCT00717236
- 13.6% vs 0% NCT00993317
- 70.6% vs 60.8% NCT01521923
- 16.7% vs 2.7% NCT02151851
- 9.4% vs 3.1% NCT00674362
- 17.3% vs 2.5% NCT00993317
- 63.1% vs 60.8% NCT01521923
- 37.7% vs 15.9% NCT00580840
- 30% vs 15.9% NCT00580840
- golimumab
- 16.1% vs 25.9%vs GolimumabNCT01715896
DAS28-CRP remission
- certolizumab pegol
- 16% vs 5.7%+10.3 vs placeboNCT00717236
- golimumab
- —Trial running · NCT03414502
HAQ-DI, change
- certolizumab pegol
- -0.5 vs -0.2−0.3 vs placeboNCT02151851
8 other results
- -0.4 vs -0.2 NCT00717236
- -1.0 vs -0.8 NCT01519791
- -0.3 vs -0.0 NCT00674362
- -0.5 vs -0.2 NCT00993317
- -0.5 vs -0.8 NCT01235598
- -0.6 vs -0.4 NCT00580840
- -0.7 vs -0.4 NCT00580840
- -0.6 vs -0.7 NCT01500278
- golimumab
- 0.1 vs 0.1±0 vs placeboNCT00264550
8 other results
- 0.5 vs 0.1 NCT00264550
- 0.4 vs 0.1 NCT00264550
- 0.3 vs 0.1 NCT00264550
- -0.3 vs 0.2 NCT01248780
- 0.5 vs 0.1 NCT00973479
- 0.4 vs 0.1 NCT00264550
- 0.4 vs 0.1 NCT00264550
- -0.4 vs -0.6 NCT01715896
Modified Sharp score, change
- certolizumab pegol
- 0.4 vs 1.6−1.2 vs placeboNCT01451203
6 other results
- 0.2 vs 1.8 NCT01519791
- 0.3 vs 0.9 NCT01451203
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- golimumab
- 1.3 vs 1.4−0.1 vs placeboNCT00264537
11 other results
- 0.1 vs 1.4 NCT00264537
- 0.7 vs 1.4 NCT00264537
- 0.4 vs 1.4 NCT00264537
- 2.2 vs 2.2 NCT00264537
- 0 vs 0 NCT00264550
- 0.2 vs 2.2 NCT00264537
- 1.3 vs 2.2 NCT00264537
- 0.0 vs 1.1 NCT00973479
- 0.7 vs 2.2 NCT00264537
- 0 vs 0 NCT00264550
- 0 vs 0 NCT00264550
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. certolizumab pegol: 14 of 14 rows · golimumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | certolizumab pegol Rows use multiple source trials | golimumab Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 81.3% (n=841)a,b,c NCT00175877 · Phase 3 8 other source trials83.3% (n=12) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 76.7% (n=43) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 90.7% (n=43) @ 52wk400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 70% (n=110) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 81.7% (n=493) @ 52wk NCT00160641 · Phase 3 · registry result, not featured evidence 74.2% (n=565) NCT00160641 · Phase 3 · registry result, not featured evidence 58.1% (n=370) @ 52wk NCT00160693 · Phase 3 · registry result, not featured evidence 57.2% (n=402) NCT00160693 · Phase 3 · registry result, not featured evidence | 13.2% (n=91) @ 52wk50 mg SCd,a,b,c NCT01004432 · Phase 3 · combination show 1 more dose9.2% (n=184) @ 52wk2 mg/kg IV NCT01004432 · Phase 3 · combination |
| Boolean Remission responder rate · % of participants | 50% (n=84) vs 35.4% (n=79) placebo @ 104wkQ2Wd,e,a,b,f NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose52.4% (n=126) vs 35.4% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination | 1.4% (n=70) vs 8.9% (n=68) Golimumab @ 24.14wk100 mge,a,b,f NCT01715896 · Phase 2 · registry result, not featured evidence |
| CDAI Clinical Remission responder rate · % of participants | 52.4% (n=84) vs 43% (n=79) placebo @ 104wkQ2Wd,e,a,b,f NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose55.6% (n=126) vs 43% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination | 5.7% (n=70) vs 17.6% (n=68) Golimumab @ 24.14wk100 mge,a,b,f NCT01715896 · Phase 2 · registry result, not featured evidence |
| DAS28-CRP absolute change · score | -2.27 vs -2.5 placebo score @ 16wke,a,b,g NCT01235598 · Phase 3 · registry result, not featured evidence | -2.11 vs -2.4 Golimumab score @ 24.14wk100 mge,a,b,g NCT01715896 · Phase 2 · registry result, not featured evidence |
| DAS28-ESR absolute change · score No placebo or comparator arm | -3.222 scorea,b,c NCT00175877 · Phase 3 3 other source trials-2.14 score @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence -2.26 score @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence -2.99 score NCT00160641 · Phase 3 · registry result, not featured evidence | 0.209 score @ 76wk50 mg SCd,a,b,c NCT01004432 · Phase 3 · combination show 3 more doses-0.136 score @ 76wk50 mg SC NCT01004432 · Phase 3 · combination -0.013 score @ 76wk50 mg SC NCT01004432 · Phase 3 · combination -0.017 score @ 76wk2 mg/kg IV NCT01004432 · Phase 3 · combination |
| DAS28-ESR Remission responder rate · % of participants | 52.4% (n=84) vs 44.3% (n=79) placebo @ 104wkQ2Wd,e,a,b,f NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose63.5% (n=126) vs 44.3% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination | 17.3% (n=70) vs 19% (n=68) Golimumab @ 24.14wk100 mge,a,b,f NCT01715896 · Phase 2 · registry result, not featured evidence |
| EULAR Good responder rate · % of participants Good Response | 71.4% (n=21) vs 66.7% (n=12) placebo @ 16wke,a,b,g Good Response NCT01235598 · Phase 3 · registry result, not featured evidence | 27.1% (n=70) vs 41.2% (n=68) Golimumab @ 24.14wk*100 mge,a,b,g Good response NCT01715896 · Phase 2 · registry result, not featured evidence · converted to % from 19 participants as posted |
| EULAR Good, Moderate responder rate · % of participants | 94% (n=84) vs 88.6% (n=79) placebo @ 104wkQ2Wd,a,h NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose98.4% (n=126) vs 88.6% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination | 81.3% (n=395) vs 40.1% (n=197) placebo @ 14wk2 mg/kg + MTXa,h NCT00973479 · Phase 3 · registry result, not featured evidence · combination 4 other source trials69% (n=129) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 89 Participants as posted 62.5% (n=128) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted 73.4% (n=128) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 94 Participants as posted 64.3% (n=129) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted |
| EULAR Moderate responder rate · % of participants Moderate Response | 23.8% (n=21) vs 25% (n=12) placebo @ 16wke,a,b,g Moderate Response NCT01235598 · Phase 3 · registry result, not featured evidence | 50% (n=70) vs 41.2% (n=68) Golimumab @ 24.14wk*100 mge,a,b,g Moderate response NCT01715896 · Phase 2 · registry result, not featured evidence · converted to % from 35 participants as posted |
| SDAI Remission responder rate · % of participants | 53.6% (n=84) vs 41.8% (n=79) placebo @ 104wkQ2Wd,e,a,b,f NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose57.1% (n=126) vs 41.8% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination | 7.2% (n=70) vs 18.9% (n=68) Golimumab @ 24.14wk100 mge,a,b,f NCT01715896 · Phase 2 · registry result, not featured evidence |
| Dropout rate | —Q2Wi NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results—Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 41.3% NCT00175877 · Phase 3 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 31.1% NCT01443364 · Phase 4 · registry result, not featured evidence 47.7%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 49.3%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence 3.7% NCT01147341 · Phase 4 · registry result, not featured evidence —400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 2.7%Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence —Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 2.4%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 4.2%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence — NCT02151851 · Phase 3 · registry result, not featured evidence · combination 55.8% NCT01519791 · Phase 3 · registry result, not featured evidence · combination 15.7%Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 11.8%Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 31.1% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 30.2%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 25%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 32.6%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 41.8%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 14.3% NCT01235598 · Phase 3 · registry result, not featured evidence 26.7% NCT00843778 · Phase 3 · registry result, not featured evidence 8.3% NCT01374971 · Phase 3 · registry result, not featured evidence 39% NCT00160641 · Phase 3 · registry result, not featured evidence 29.4%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 8.3% NCT00753454 · Phase 3 · registry result, not featured evidence 9.4% NCT00717236 · Phase 3 · registry result, not featured evidence 58.5% NCT00160693 · Phase 3 · registry result, not featured evidence 12.5%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 29.3%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 23.5%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 19.5%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 29.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 30.3% NCT04740814 · Phase 1 · registry result, not featured evidence | 36.5%100 mg + placeboj NCT00264537 · Phase 3 show 35 more results—100 mg SC NCT00264537 · Phase 3 —50 mg SC NCT00264537 · Phase 3 37.7%100 mg + methotrexate NCT00264537 · Phase 3 · combination 31.4%50 mg + methotrexate NCT00264537 · Phase 3 · combination 30.8%100 mg + placebo NCT00264550 · Phase 3 —100 mg SC injections NCT00264550 · Phase 3 —50 mg SC injections NCT00264550 · Phase 3 33.7%100 mg + MTX NCT00264550 · Phase 3 · combination 19.1%50 mg + MTX NCT00264550 · Phase 3 · combination —50mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —2mg/kg IV NCT01004432 · Phase 3 · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 17.5%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 11.4%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination —100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 56.2%100 mg NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 60.1%50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 8.3%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 15.7%100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 23.5%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 14.7%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 20%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 29.4%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —Q2Wi NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results—Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 16.1% NCT00175877 · Phase 3 — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination — NCT01443364 · Phase 4 · registry result, not featured evidence 11.7%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 7.9%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence — NCT01147341 · Phase 4 · registry result, not featured evidence —400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 0.9%Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence —Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 1.6%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 2.1%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence — NCT02151851 · Phase 3 · registry result, not featured evidence · combination — NCT01519791 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination —Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 5.6% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 14%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 16.7%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 14%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 13.6%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 10.7% NCT01235598 · Phase 3 · registry result, not featured evidence 11.5% NCT00843778 · Phase 3 · registry result, not featured evidence — NCT01374971 · Phase 3 · registry result, not featured evidence 18% NCT00160641 · Phase 3 · registry result, not featured evidence 4.7%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT00753454 · Phase 3 · registry result, not featured evidence 3.9% NCT00717236 · Phase 3 · registry result, not featured evidence 24.1% NCT00160693 · Phase 3 · registry result, not featured evidence 6.3%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 6.9%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 8.2%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 3.7%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 9.1% NCT04740814 · Phase 1 · registry result, not featured evidence | 20.1%100 mg + placeboj NCT00264537 · Phase 3 show 35 more results—100 mg SC NCT00264537 · Phase 3 —50 mg SC NCT00264537 · Phase 3 21.4%100 mg + methotrexate NCT00264537 · Phase 3 · combination 15.1%50 mg + methotrexate NCT00264537 · Phase 3 · combination 13.5%100 mg + placebo NCT00264550 · Phase 3 —100 mg SC injections NCT00264550 · Phase 3 —50 mg SC injections NCT00264550 · Phase 3 15.7%100 mg + MTX NCT00264550 · Phase 3 · combination 10.1%50 mg + MTX NCT00264550 · Phase 3 · combination —50mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —2mg/kg IV NCT01004432 · Phase 3 · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 8.1%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 5.3%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination —100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 17.6%100 mg NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 14.4%50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 4.5%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 8.8%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 2.9%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 5.7%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 11.8%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%Q2Wi NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results0%Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 41.6% NCT00175877 · Phase 3 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.1% NCT01443364 · Phase 4 · registry result, not featured evidence 10.6%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 8.7%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence 2.9% NCT01147341 · Phase 4 · registry result, not featured evidence 2.9%400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 7.1%200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence 1.8%Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 2%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 6.3%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence 6.3% NCT02151851 · Phase 3 · registry result, not featured evidence · combination 10.6% NCT01519791 · Phase 3 · registry result, not featured evidence · combination 4.8%Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 7.1%Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 10.7% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 37.2%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 25%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 39.5%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 36.4%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence — NCT01235598 · Phase 3 · registry result, not featured evidence 19.2% NCT00843778 · Phase 3 · registry result, not featured evidence 0% NCT01374971 · Phase 3 · registry result, not featured evidence 35.3% NCT00160641 · Phase 3 · registry result, not featured evidence 9.4%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 3% NCT00753454 · Phase 3 · registry result, not featured evidence 6.1% NCT00717236 · Phase 3 · registry result, not featured evidence 45.8% NCT00160693 · Phase 3 · registry result, not featured evidence 5.2%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 11.2%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 5.9%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.9%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 6.1% NCT04740814 · Phase 1 · registry result, not featured evidence | —100 mg + placeboj NCT00264537 · Phase 3 show 35 more results38.7%100 mg SC NCT00264537 · Phase 3 32%50 mg SC NCT00264537 · Phase 3 —100 mg + methotrexate NCT00264537 · Phase 3 · combination —50 mg + methotrexate NCT00264537 · Phase 3 · combination —100 mg + placebo NCT00264550 · Phase 3 45.7%100 mg SC injections NCT00264550 · Phase 3 31.4%50 mg SC injections NCT00264550 · Phase 3 —100 mg + MTX NCT00264550 · Phase 3 · combination —50 mg + MTX NCT00264550 · Phase 3 · combination 4.4%50mg SC NCT01004432 · Phase 3 · combination 2.7%50 mg SC NCT01004432 · Phase 3 · combination 4.6%50 mg SC NCT01004432 · Phase 3 · combination 4.7%50 mg SC NCT01004432 · Phase 3 · combination 5.4%2mg/kg IV NCT01004432 · Phase 3 · combination 19.7%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 6.1%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination 33.3%100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence —100 mg NCT00299546 · Phase 3 · registry result, not featured evidence 34.7%50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 6%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence 2.7%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence 6.9%2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination 6.8%50 mg NCT00361335 · Phase 3 · registry result, not featured evidence 6.3%4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence 13.3%2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence 9.1%50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 14%4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 13.7%2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 2.9%100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 15.2%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 14.3%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 18.9%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 15.6%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 34 more resultsnasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination influenza 11.4% arthralgia 6.8% bronchitis 5.3% NCT01443364 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 10.4% urinary tract infection 10.4% bronchitis 6% NCT01255761 · Phase 4 · registry result, not featured evidence urinary tract infection 10.6% upper respiratory tract infection 10% sinusitis 7.6% NCT01255761 · Phase 4 · registry result, not featured evidence upper respiratory infections 18.5% (placebo 0%) rash 11.8% (placebo 0%) bronchitis 8.8% (placebo 0%) NCT01147341 · Phase 4 · registry result, not featured evidence 400 mg upper respiratory tract infection 11.6% (placebo 14.5%) urinary tract infection 8.7% (placebo 10.1%) arthralgia 7.2% (placebo 2.9%) NCT00580840 · Phase 4 · registry result, not featured evidence · combination 200 mg upper respiratory tract infection 7.1% (placebo 14.5%) urinary tract infection 7.1% (placebo 10.1%) arthralgia 1.4% (placebo 2.9%) NCT00580840 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 9.1% (placebo 5.3%) headache 7.3% (placebo 13.2%) nausea 5.5% (placebo 5.3%) NCT00993668 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 15.5% anaemia 5.6% liver function test abnormal 4.4% NCT02319642 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 13.7% anaemia 5.3% liver function test abnormal 5.3% NCT02319642 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 15.8% (placebo 13.3%) latent tuberculosis 7.6% (placebo 6.2%) liver function test abnormal 7% (placebo 3.5%) NCT02151851 · Phase 3 · registry result, not featured evidence · combination nausea 12.6% (placebo 10.1%) upper respiratory tract infection 10.9% (placebo 5.1%) urinary tract infection 7.3% (placebo 7.4%) NCT01519791 · Phase 3 · registry result, not featured evidence · combination Q2W urinary tract infection 6% (placebo 2.5%) nasopharyngitis 4.8% (placebo 6.2%) hypercholesterolaemia 2.4% (placebo 3.7%) NCT01521923 · Phase 3 · registry result, not featured evidence · combination Q4W nasopharyngitis 10.2% (placebo 6.2%) hypercholesterolaemia 6.3% (placebo 3.7%) latent tuberculosis 5.5% (placebo 0%) NCT01521923 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 44% (placebo 34.4%) hepatic function abnormal 32.1% (placebo 30.6%) nausea 24.5% (placebo 19.1%) NCT01451203 · Phase 3 · registry result, not featured evidence · combination 400 mg nasopharyngitis 44.2% pharyngitis 16.3% bronchitis 14% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg rheumatoid arthritis 25% bronchitis 16.7% constipation 16.7% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 41.9% eczema 27.9% upper respiratory tract infection 20.9% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 38.2% eczema 18.2% pharyngitis 15.5% NCT00850343 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.2% diarrhoea 6.2% nasopharyngitis 6.2% NCT00843778 · Phase 3 · registry result, not featured evidence flare of rheumatoid arthritis 8.3% headache 8.3% injection site reaction 8.3% NCT01374971 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 16% hypertension 13.6% rheumatoid arthritis 13.4% NCT00160641 · Phase 3 · registry result, not featured evidence 200mg upper respiratory tract infection 14.1% (placebo 11.9%) nasopharyngitis 11.8% (placebo 9.5%) abdominal pain upper 5.9% (placebo 4.8%) NCT00993317 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 13.7% NCT00753454 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.3% (placebo 5.3%) headache 5.4% (placebo 5.3%) rheumatoid arthritis 4.4% (placebo 7.7%) NCT00717236 · Phase 3 · registry result, not featured evidence nasopharyngitis 35.1% upper respiratory tract infection 23.1% back pain 22.4% NCT00160693 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 10.4% (placebo 11.2%) upper respiratory tract infection 6.3% (placebo 4.1%) urinary tract infection 6.3% (placebo 5.1%) NCT00674362 · Phase 3 · registry result, not featured evidence 200mg nasopharyngitis 17.2% (placebo 14%) rash 8.6% (placebo 0%) eczema 5.2% (placebo 2.6%) NCT00791921 · Phase 3 · registry result, not featured evidence 400 mg nasopharyngitis 15.3% (placebo 11.7%) hepatic function abnormal 5.9% (placebo 5.2%) bronchitis 4.7% (placebo 1.3%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 200 mg nasopharyngitis 13.4% (placebo 11.7%) pharyngitis 6.1% (placebo 3.9%) rash 4.9% (placebo 1.3%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 100 mg hepatic function abnormal 11.1% (placebo 5.2%) nasopharyngitis 11.1% (placebo 11.7%) pharyngitis 6.9% (placebo 3.9%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence upper respiratory tract infection 9.1% nausea 6.1% rheumatoid arthritis 6.1% NCT04740814 · Phase 1 · registry result, not featured evidence | show 26 more results50 mg SC upper respiratory tract infection 26.2% alanine aminotransferase increased 18% bronchitis 15.1% NCT00264537 · Phase 3 100 mg SC injections upper respiratory tract infection 34.8% cough 19% nasopharyngitis 19% NCT00264550 · Phase 3 50 mg SC injections upper respiratory tract infection 37.1% cough 22.9% bronchitis 17.1% NCT00264550 · Phase 3 50 mg SC upper respiratory tract infection 9.3% depression 5.3% sinusitis 5.3% NCT01004432 · Phase 3 · combination 50 mg SC upper respiratory tract infection 6.7% headache 5.5% urinary tract infection 5.5% NCT01004432 · Phase 3 · combination 50 mg SC upper respiratory tract infection 6.1% urinary tract infection 6.1% sinusitis 5.7% NCT01004432 · Phase 3 · combination 2mg/kg IV upper respiratory tract infection 8.2% sinusitis 7.1% bronchitis 6% NCT01004432 · Phase 3 · combination 2 mg/kg + MTX upper respiratory tract infection 13.7% bronchitis 9.4% rheumatoid arthritis 8.4% NCT00973479 · Phase 3 · registry result, not featured evidence · combination 50 mg upper respiratory tract infection 19.1% liver function test abnormal 6.1% anaemia 1.5% NCT01248780 · Phase 3 · registry result, not featured evidence · combination 100 mg SC injections upper respiratory tract infection 31.2% nasopharyngitis 18.8% rheumatoid arthritis 16.7% NCT00299546 · Phase 3 · registry result, not featured evidence 50 mg SC injections upper respiratory tract infection 25.5% sinusitis 19.4% headache 14.3% NCT00299546 · Phase 3 · registry result, not featured evidence 50 mg subcutaneous nasopharyngitis 0% upper respiratory tract infection 0% NCT00975130 · Phase 3 · registry result, not featured evidence 50 mg subcutaneous nasopharyngitis 7.1% upper respiratory tract infection 2.4% NCT00975130 · Phase 3 · registry result, not featured evidence 2 mg/kg intravenous + 50 mg subcutaneous upper respiratory tract infection 6.1% nasopharyngitis 5.3% NCT00975130 · Phase 3 · registry result, not featured evidence · combination 50 mg upper respiratory tract infection 8.5% (placebo 9.3%) nasopharyngitis 7.7% (placebo 5.4%) rheumatoid arthritis 5.1% (placebo 4.7%) NCT00361335 · Phase 3 · registry result, not featured evidence 4 mg/kg upper respiratory tract infection 12.6% (placebo 9.3%) rheumatoid arthritis 9.4% (placebo 4.7%) bronchitis 6.3% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence 2 mg/kg rheumatoid arthritis 15.6% (placebo 4.7%) upper respiratory tract infection 10.9% (placebo 9.3%) bronchitis 7.8% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence 50 mg upper respiratory tract infection 7.2% (placebo 9.3%) rheumatoid arthritis 6.9% (placebo 4.7%) bronchitis 5.3% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 4 mg/kg upper respiratory tract infection 12.2% (placebo 9.3%) nausea 10.7% (placebo 7%) bronchitis 7.7% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 2 mg/kg upper respiratory tract infection 12.1% (placebo 9.3%) nausea 11% (placebo 7%) headache 9.3% (placebo 10.1%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 100 mg nasopharyngitis 5.7% headache 4.3% hepatic enzyme increased 4.3% NCT01715896 · Phase 2 · registry result, not featured evidence 100 mg every 4 weeks headache 27.3% (placebo 20.6%) nausea 21.2% (placebo 5.9%) upper respiratory tract infection 15.2% (placebo 20.6%) NCT00207714 · Phase 2 · registry result, not featured evidence 100 mg every 2 or 4 weeks injection site erythema 28.6% (placebo 11.8%) nasopharyngitis 22.9% (placebo 8.8%) nausea 22.9% (placebo 5.9%) NCT00207714 · Phase 2 · registry result, not featured evidence 50 mg every 4 weeks headache 21.6% (placebo 20.6%) nasopharyngitis 21.6% (placebo 8.8%) rheumatoid arthritis 21.6% (placebo 14.7%) NCT00207714 · Phase 2 · registry result, not featured evidence 50 mg every 2 or 4 weeks nausea 25% (placebo 5.9%) rheumatoid arthritis 21.9% (placebo 14.7%) headache 18.8% (placebo 20.6%) NCT00207714 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 3 versus Phase 2.
- fAssessment timepoints differ: 104 weeks versus 24.14 weeks.
- gAssessment timepoints differ: 16 weeks versus 24.14 weeks.
- hAssessment timepoints differ: 104 weeks versus 14 weeks.
- iPopulation comparability has not been reviewed for 39 of these studies.
- jPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
certolizumab pegol
show 20 more results
show 20 more results
show 9 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 7 more results
show 5 more results
show 1 more result
+ 87 further endpoints in the CSV export.
golimumab
show 4 more results
show 6 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 23 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · golimumab's landscape